Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600267 Zhejiang Hisun Pharmaceutical Co.,Ltd.

Trading 08-31 10:21:28

11.87

-0.33

-2.70%

High12.11	Low11.85	Vol11.05M
Open12.06	D1 Closing12.20	Amplitude2.13%
Mkt Cap14.01B	Tradable Cap14.01B	Total Shares1.18B
T/O132.00M	T/O Rate0.94%	Tradable Shares1.18B
P/B1.6	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600267","market":"SH","secType":"STK","nameCN":"Zhejiang Hisun Pharmaceutical Co.,Ltd.","latestPrice":11.87,"timestamp":1788142888000,"preClose":12.2,"halted":0,"volume":11051403,"delay":0,"changeRate":-0.027,"floatShares":1180000000,"shares":1180000000,"eps":0.744,"marketStatus":"Trading","change":-0.33,"latestTime":"08-31 10:21:28","open":12.06,"high":12.11,"low":11.85,"amount":132000000,"amplitude":0.0213,"askPrice":11.88,"askSize":323,"bidPrice":11.87,"bidSize":504,"shortable":0,"etf":0,"ttmEps":0.744,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1788147000000},"marketStatusCode":2,"adr":0,"adjPreClose":12.2,"symbolType":"stock","openAndCloseTimeList":[[1788139800000,1788147000000],[1788152400000,1788159600000]],"highLimit":13.42,"lowLimit":10.98,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1180272096,"isCdr":false,"pbRate":1.6,"roa":"--","peRate":15.954301,"roe":"7.2%","epsLYR":0.46,"committee":0.637099,"marketValue":14010000000,"turnoverRate":0.0094,"status":1,"floatMarketCap":14010000000},"requestUrl":"/m/hq/s/600267/tweets","defaultTab":"tweets","newsList":[{"id":"1186214666","title":"Zhejiang Hisun Pharmaceutical Schedules Investor Meeting for First-Half 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1186214666","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186214666?lang=en_us&edition=fundamental","pubTime":"2026-08-25 21:21","pubTimestamp":1787664083,"startTime":"0","endTime":"0","summary":"On August 25, Zhejiang Hisun Pharmaceutical Co.,Ltd. announced that its investor communication session covering the first-half 2026 financial results is set to take place on September 3, 2026, from...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600267","BK0239","BK0188","BK0060","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662381357","title":"Zhejiang Hisun Pharmaceutical H1 Net Profit up 112.8% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2662381357","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662381357?lang=en_us&edition=fundamental","pubTime":"2026-08-25 17:47","pubTimestamp":1787651256,"startTime":"0","endTime":"0","summary":"BRIEF-Zhejiang Hisun Pharmaceutical H1 Net Profit Up 112.8% Y/YAug 25 (Reuters)-Zhejiang Hisun Pharmaceutical Co Ltd600267.SS:H1 NET PROFIT UP 112.8% Y/YSource textFurther company coverage:600267.SS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL4N44M0KB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0060","BK0239","BK0028","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656153511","title":"Zhejiang Hisun Pharmaceutical Wins Pre-Bids for Five Drugs Under China Procurement System","url":"https://stock-news.laohu8.com/highlight/detail?id=2656153511","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656153511?lang=en_us&edition=fundamental","pubTime":"2026-08-04 16:16","pubTimestamp":1785831373,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical  and subsidiary Hanhui Pharmaceutical won pre-bids for five products under China's drug procurement program, according to a Tuesday filing with the Shanghai bourse.Three of the drugs are antibiotic injections, including imipenem and cilastatin sodium, vancomycin hydrochloride, and teicoplanin.Two other products, tacrolimus for injection and epirubicin hydrochloride, are chemotherapy drugs.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","BK0188","600267","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134729119","title":"Zhejiang Hisun Pharmaceutical Secures Tentative Selection for Five Products in National Bulk Drug Procurement","url":"https://stock-news.laohu8.com/highlight/detail?id=1134729119","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134729119?lang=en_us&edition=fundamental","pubTime":"2026-08-03 15:53","pubTimestamp":1785743637,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that on July 31, 2026, the company and its wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd., participated in the bidding process...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","600267","BK0239","BK0060","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654090579","title":"Zhejiang Hisun Pharmaceutical Receives US FDA Abbreviated New Drug Application Approval for Leukemia Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2654090579","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654090579?lang=en_us&edition=fundamental","pubTime":"2026-07-27 15:34","pubTimestamp":1785137689,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical  received an abbreviated new drug application approval from the U.S. Food and Drug Administration for its fludarabine phosphate injection, according to a Saturday filing with the Shanghai bourse.The injection is indicated for the treatment of adult B-cell chronic lymphocytic leukemia for patients unresponsive to at least one prior alkylating agent-containing therapy or whose disease has progressed during treatment.Global sales of the injection reached $23.5 million in 2025, according to market data cited in the filing.Hisun has invested 10 million yuan for research and development of the drug.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600267","BK4585","BK0060","BK0239","BK0028","BK4588","BK0188","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153375470","title":"Zhejiang Hisun Pharmaceutical Subsidiary Obtains US FDA Clearance for Generic Cancer Drug Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1153375470","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153375470?lang=en_us&edition=fundamental","pubTime":"2026-07-24 16:58","pubTimestamp":1784883503,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) has announced that its wholly-owned subsidiary, Hisun Pharmaceutical (Hangzhou) Co., Ltd., has received notification from the U.S. Food and Drug...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK4588","LABU","BK0188","600267","BK0028","BK0239","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650643189","title":"Zhejiang Hisun Pharmaceutical Sees H1 Net Profit up 100.62%-117.34% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2650643189","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650643189?lang=en_us&edition=fundamental","pubTime":"2026-07-10 17:48","pubTimestamp":1783676929,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nL4N43C0O4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["600267","BK0060","BK0239","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453735","title":"Zhejiang Hisun Pharmaceutical Gets Approval for Cytomegalovirus Medication","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453735","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647453735?lang=en_us&edition=fundamental","pubTime":"2026-06-30 18:30","pubTimestamp":1782815413,"startTime":"0","endTime":"0","summary":"China's drug regulator approved Zhejiang Hisun Pharmaceutical's (SHA:600267) letermovir antiviral active ingredient, according to a Tuesday filing with the Shanghai bourse.The drug is indicated for cytomegalovirus prevention and cure in adults and children weighing 6 kilograms or more.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK0239","BK0188","BK0060","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182717769","title":"Zhejiang Hisun Pharmaceutical Receives Approval for Letermovir Active Ingredient","url":"https://stock-news.laohu8.com/highlight/detail?id=1182717769","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182717769?lang=en_us&edition=fundamental","pubTime":"2026-06-29 16:54","pubTimestamp":1782723260,"startTime":"0","endTime":"0","summary":"An announcement from Zhejiang Hisun Pharmaceutical Co.,Ltd. (ASX: 600267) indicates that the company has recently obtained the \"Chemical Drug Substance Marketing Authorization Approval Notice\" for...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","IPOS","600267","BK0239","BK0060","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168403352","title":"Zhejiang Hisun Pharmaceutical's Finerenone API Receives Market Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1168403352","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168403352?lang=en_us&edition=fundamental","pubTime":"2026-06-11 15:54","pubTimestamp":1781164462,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (ASX: 600267) has announced that it recently received the \"Chemical Active Pharmaceutical Ingredient Marketing Application Approval Notice\" for finerenone from...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0188","600267","BK0028","BK0239","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637367084","title":"Hisun Pharmaceutical Clinches NMPA Drug Registration for Prostate Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2637367084","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637367084?lang=en_us&edition=fundamental","pubTime":"2026-05-22 12:21","pubTimestamp":1779423692,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical (SHA:600267) received a drug registration certificate from China's National Medical Products Administration for its apalutamide tablets, according to a Friday disclosure on the Shanghai bourse.The drug is used to treat prostate cancer.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0239","BK0060","600267","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140817235","title":"Hisun Pharmaceutical Obtains Approval for Apalutamide Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1140817235","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140817235?lang=en_us&edition=fundamental","pubTime":"2026-05-21 17:04","pubTimestamp":1779354281,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) has announced the receipt of a drug registration certificate for Apalutamide Tablets from the National Medical Products Administration. The tablets...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0239","BK0188","BK0060","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630914364","title":"BRIEF-Zhejiang Hisun Pharmaceutical Q1 Net Profit Up 83.1% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2630914364","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630914364?lang=en_us&edition=fundamental","pubTime":"2026-04-27 17:44","pubTimestamp":1777283081,"startTime":"0","endTime":"0","summary":"BRIEF-Zhejiang Hisun Pharmaceutical Q1 Net Profit Up 83.1% Y/YApril 27 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd 600267.SS:Q1 NET PROFIT UP 83.1% Y/YSource textFurther company coverage: 600267.SS (Reporting by Beijing Newsroom) ((yukun.zhang@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nL4N41A0PC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","600267","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199587339","title":"Hisun Pharma Q1 Net Profit Attributable to Shareholders Jumps 83.13% to 356 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1199587339","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199587339?lang=en_us&edition=fundamental","pubTime":"2026-04-15 17:12","pubTimestamp":1776244343,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) has released its preliminary financial results for the first quarter of 2026. During the reporting period, the company achieved operating revenue...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0028","600267","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127774883","title":"Zhejiang Hisun Pharmaceutical Soars to Daily Limit in Sharp Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1127774883","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127774883?lang=en_us&edition=fundamental","pubTime":"2026-04-15 12:51","pubTimestamp":1776228707,"startTime":"0","endTime":"0","summary":"A-shares' three major indices showed mixed performance, while the GPU sector experienced a strong upward trend. Multiple stocks in the pharmaceutical sector surged by the daily limit. On the morning...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0188","600267","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197239794","title":"Hisun Pharma Reports 2025 Earnings with Net Profit Attributable to Shareholders of 541 Million Yuan, Down 10.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197239794","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197239794?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:20","pubTimestamp":1775564423,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) has released its annual report for 2025. During the reporting period, the company achieved revenue of 105.5 billion yuan, representing a...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600267","BK0028","BK0239","BK0060","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622848880","title":"Zhejiang Hisun Pharmaceutical Subsidiary Gets Supplementary Drug Approval for Anti-Leukemia Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2622848880","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622848880?lang=en_us&edition=fundamental","pubTime":"2026-03-27 14:41","pubTimestamp":1774593687,"startTime":"0","endTime":"0","summary":"China's drug regulator granted Zhejiang Hisun Pharmaceutical  subsidiary Hanhui Pharmaceutical a supplementary drug approval for its Idarubicin Hydrochloride Injection, according to a Friday filing with the Shanghai bourse.The injection will help induce remission of treatment-nave, as well as relapsed and refractory acute non-lymphocytic leukemia in adults.As stated in the filing, it also serves as a treatment for acute lymphoblastic leukemia.Shares rose 4% during afternoon trading on Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0028","BK0060","600267","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620942965","title":"China Approves Hisun Subsidiary's Clinical Trial for High Cholesterol Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2620942965","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620942965?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:23","pubTimestamp":1773746581,"startTime":"0","endTime":"0","summary":"China's drug regulator approved Zhejiang Hisun Pharmaceutical  subsidiary Hanhui Pharmaceutical's clinical trial for its Hybomimab atorvastatin calcium tablets, according to a Tuesday disclosure to the Shanghai bourse.The drug is indicated for patients with high cholesterol levels whose low-density lipoprotein levels could not be achieved with solo statin therapy, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0028","BK0060","BK0239","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173944726","title":"Hisun Pharma Receives Clinical Trial Approval for Hybomet-Atorvastatin Calcium Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1173944726","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173944726?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:55","pubTimestamp":1773662155,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that its wholly-owned subsidiary, Hisun Pharmaceutical Co., Ltd., has received a drug clinical trial approval notice from the National...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0060","600267","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616631346","title":"Zhejiang Hisun Pharmaceutical Secures Approval for Canine Antifungal Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2616631346","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616631346?lang=en_us&edition=fundamental","pubTime":"2026-03-03 18:34","pubTimestamp":1772534050,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical  unit Hisun Animal Health obtained veterinary drug approval from China's agriculture ministry for terbinafine hydrochloride tablets.The drug, with brand name Fenlishu, is indicated for canine skin infections caused by Microsporum canis, according to a Tuesday filing with the Shanghai bourse.The approval is valid until Feb. 13, 2031.Shares of the company were down 2% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0060","BK0028","600267","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788142894849,"stockEarnings":[{"period":"1week","weight":-0.0673},{"period":"1month","weight":0.0304},{"period":"3month","weight":0.2145},{"period":"6month","weight":0.1947},{"period":"1year","weight":0.1505},{"period":"ytd","weight":0.2588}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.0323},{"period":"3month","weight":-0.0286},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0283},{"period":"ytd","weight":-0.0042}],"compareStock":{"symbol":"000001.SH","name":"SSE Comp"},"companyName":"浙江海正药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"48826人(较上一季度增加2.42%)","perCapita":"24173股","listingDate":"2000-07-25","address":"浙江省台州市椒江区外沙路46号","registeredCapital":"118027万元","survey":"　　浙江海正药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是海博麦布片（赛斯美）、注射用哌拉西林钠他唑巴坦钠（特治星）、盐酸米诺环素胶囊（玫满）、茚达特罗格隆溴铵吸入粉雾剂（杰润）、注射用丝裂霉素、瑞舒伐他汀钙片（海舒严）、注射用亚胺培南西司他丁钠（俊特）、米尔贝肟吡喹酮片（海乐妙）、丁二磺酸腺苷蛋氨酸肠溶片（喜美欣）、英夫马芬净。","listedPrice":11.83},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Zhejiang Hisun Pharmaceutical Co.,Ltd.,600267,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票老虎,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票老虎国际,Zhejiang Hisun Pharmaceutical Co.,Ltd.行情,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票行情,Zhejiang Hisun Pharmaceutical Co.,Ltd.股价,Zhejiang Hisun Pharmaceutical Co.,Ltd.股市,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票价格,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票交易,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票购买,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction